日韩A∨无码成人精品国产,激情A片久久久久久久,无码天堂va亚洲va在线va免费无码又爽又刺激高潮虎虎视频,伊人无码精品久久一区二区,婷婷激情五月一区二区三区播放中美女 赤裸 一区二区三区,精品亚洲成A人片在线观看少妇,亚洲欧美综合国产不卡,国产精品亚洲а∨天堂免

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Enhanced T Cell Platforms

Enhanced T Cell Platforms (HyperTCell ®), including HyperCART® and HyperTCRT, are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells. HyperCART® takes improving the clinical efficacy of CAR-T in solid tumors as its core purpose. Based on the concept of synthetic biology, HyperCART® adopts efficient gene delivery system to target tumor cells specifically, reverse the immuno suppressive state and improve the predicament of difficult infiltration and poor efficacy of traditional CAR-T in solid tumor therapy. HyperTCRT is based on the discovery and validation of TCR targeting tumor-specific neoantigen mutations, combined with efficient gene editing technology, to develop a new generation of enhanced TCR-T cells to improve the effectiveness of solid tumor therapy.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
后入内射国产一区二区| 久久国产综合精品五月天| 色综合a在线中文字幕| 激情综合色综合啪啪开心| AV麻豆男人的天堂在线观看| 亚洲免费福利精品日韩视频| 国产在线视频福利资源站| 色噜噜狠狠色综合网| 国产在线拍揄自揄视频不卡99| 久久精品国产99久久丝袜| 欧美极度残忍另类XX| 国产91精选在线观看麻豆| 无码人妻毛片丰满熟妇区毛片| 久久久久精品国产三级| 亚洲欧美v国产一区二区| 中文字幕精品久久久久人妻| 91麻豆精品国产高清在线| 一级AAA特黄A∨片免费观看| 国产午夜精品一区二区三区| 精品视频一区二区三区在线观看| 日本一卡二卡3卡四卡网站精品| 国产精品边做奶水狂喷无码| 无码乱人伦一区二区亚洲一| 日韩中文高清在线专区| 日韩欧美一区二区三区在线播放| 久久精品国产亚洲AⅤ无码| 精品一区在线观看视频网站| 久久人人爽人人爽人人片AV超碰| 曰批视频免费40分钟野战| 久久精品无码精品免费专区| 日日噜噜夜夜狠狠视频欧美人| 最近中文字幕2019视频1| 国产成人亚综合精品首页| 国产精品无码一区二区三区| 色婷婷综合中文久久一本| 狠狠色丁香久久婷婷综合五月| 国产日韩精品欧美一区灰灰| 深夜A级毛片催情精视频免费| 国产高清av在线免费观看一区二区| 国产精品免费区二区三区观看| 一级做a爰片久久毛片A片秋霞天|